A corporate venture capital arm of a global pharmaceutical company invests in early-stage healthcare innovation. The firm primarily targets Pre-Seed and Seed financings, with initial investments generally ranging from approximately $500K to $2M. The firm evaluates opportunities globally, with a particular focus on companies based in the United States. The firm is open to both leading and co-investing and may seek board representation when serving as the lead investor. While primarily financially driven, the firm can also leverage the strategic capabilities and resources of its affiliated pharmaceutical organization when relevant to a portfolio company. 

The firm seeks innovative science addressing significant unmet medical needs, with a primary focus on therapeutics and technologies enabling therapeutic development. Modalities and technologies of interest include cell and gene therapies, small molecules, radiopharmaceuticals, CRISPR and other gene-editing approaches, and data-driven technologies such as AI-enabled drug discovery. Key therapeutic areas include oncology, neurology, and rare diseases. The firm may also selectively consider less-invasive diagnostic technologies. The firm primarily targets companies with programs ranging from preclinical development through Phase I. 

From a company and management team perspective, the firm prioritizes promising science supported by strong and defensible intellectual property. As an active investor, the firm supports portfolio companies through its industry network, investment expertise, and broader strategic resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global pharmaceutical company pursues external innovation through in-licensing, strategic partnerships, and other business development relationships with biotechnology and pharmaceutical companies. The firm evaluates opportunities globally and seeks differentiated therapeutic assets that can complement and expand its existing development and commercial portfolio. 

The firm is primarily focused on oncology and neuroscience, with particular interest in hematologic malignancies, solid tumors, and sleep disorders. Additional areas of interest include pediatric oncology, select central nervous system disorders, and rare diseases, particularly conditions affecting pediatric populations. The firm generally prefers therapeutic assets that have demonstrated proof-of-concept in humans, although earlier-stage programs may be considered when they demonstrate particularly strong strategic alignment in the firm’s core areas of oncology or sleep medicine. 

From a company and management team perspective, the firm seeks partners developing differentiated therapeutics with compelling scientific rationale, meaningful clinical potential, and the ability to address significant unmet medical needs. The firm is flexible regarding company geography and evaluates partnership opportunities based primarily on the quality of the underlying asset, clinical evidence, strategic fit, and potential to complement its therapeutic expertise and global development capabilities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A strategic investment arm of a global consumer health and personal care company with a long-standing presence has made strategic investments for several years and typically deploys approximately $500K–$2M as an initial investment in companies that complement its existing businesses and long-term innovation priorities. The firm evaluates opportunities globally and combines financial investment with potential access to its parent company’s research, commercial, supply chain, and international market capabilities. 

The firm primarily focuses on therapeutics and drug discovery technologies addressing dermatology, skin-related diseases, aging, and longevity. The firm invests in both preclinical and early clinical-stage companies and seeks differentiated science with the potential to address meaningful needs in skin health and adjacent areas. Medical devices, diagnostics, and digital health are not current investment priorities, although the firm may selectively consider enabling technologies with strong strategic relevance to its core healthcare, personal care, or related innovation activities. 

From a company and management team perspective, the firm seeks compelling technologies with clear strategic relevance, scalability, and the potential for collaboration with established global brands. The firm is particularly interested in opportunities that can leverage its broader R&D, consumer, supply chain, and commercialization capabilities. Investments may involve minority equity positions alongside strategic collaborations, with the firm emphasizing opportunities where it can provide meaningful value beyond financial capital. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm in the US invests in healthcare companies, specifically medtech and enterprise healthcare IT. The firm manages a total of $125 million in assets. The firm writes $2M-$4M checks into Series A and B rounds where the company is post-FDA and generating commercial revenue. The firm looks to invest in companies located in the US except for NYC north and Silicon Valley. 
 
The firm is looking for Life Science companies primarily in areas of Medical Device and Healthcare IT, although the firm will also consider Digital Health, Diagnostics, and companies with developed and approved therapeutics. The firm is broadly open to all subsectors and indications within these areas but tend to focus more on intraoperative technologies such as orthopedics, surgical navigation/tools, nerve, or oncology. 
 
Ideal companies have $1 million or more of run-rate revenue; gross margins of 50% or higher; and equity capital needs of less than $10 million at the time of investment. The firm looks to take a board seat into companies and take a very active role in helping the company expand through their network of strategic partners. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an early-stage venture capital fund established by a group of experienced medical device industry professionals in Asia. The firm typically invests approximately $700K–$3M in companies raising Angel, Pre-Series A, Series A, and Series B financings. The firm invests through a local-currency fund and therefore places a strong emphasis on international companies willing to establish a joint venture or meaningful operating presence in Asia. The firm’s partners leverage extensive medical device industry experience and local networks to help portfolio companies establish and grow their businesses in the Asian market. 

The firm primarily invests in medical devices and in vitro diagnostics, with particular expertise in cardiology, neuromodulation, diagnostic technologies, and medical imaging. The firm is also interested in R&D services and AI-enabled healthcare technologies, particularly technologies that use artificial intelligence to improve medical imaging, diagnostic accuracy, or clinical efficiency. While these areas represent the firm’s core expertise, the firm remains open to other differentiated medical technologies with strong development and commercialization potential. 

From a company and management team perspective, the firm strongly prefers opportunities with a clear Asia strategy and companies willing to collaborate closely with its investment partners. The firm can support international companies through local industry relationships, access to industrial and commercialization networks, and assistance in identifying potential non-dilutive funding opportunities. The firm seeks management teams that are receptive to strategic involvement and can leverage the firm’s operating experience and local resources to establish and expand their presence in Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an early-stage investment firm headquartered in Asia. The firm is actively seeking Seed through Series A opportunities and can invest up to approximately $3M over the lifecycle of a portfolio company. The firm evaluates opportunities across Asia, North America, and Europe and provides both financial and strategic support to emerging healthcare companies. 

The firm invests broadly across life sciences, including therapeutics, medical devices, diagnostics, and digital health. The firm is indication-agnostic and seeks cutting-edge technologies addressing a wide range of healthcare needs. As an early-stage investor, the firm is comfortable evaluating technologies at the preclinical or early development stage and maintains a flexible approach to different technologies and business models. 

From a company and management team perspective, the firm does not impose specific requirements. The firm can act as either a lead investor or co-investor, although the firm generally seeks a more active role and may prefer to lead when investing in very early-stage companies. Through relationships with healthcare organizations and strategic partners, the firm can also provide portfolio companies with operational, commercialization, and business development support. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A Europe-based investment group invests through an evergreen structure. The firm typically deploys approximately $2–$20M per company and invests primarily in private companies with a focus on the Nordic region. Investments are generally structured as equity, although convertible loans may also be considered. The firm has a long track record of supporting healthcare companies through growth and public-market exits and typically seeks a small number of new investments each year. 

Within life sciences and healthcare, the firm focuses on therapeutics, medical technology, and healthtech. For therapeutics, the firm generally targets clinical-stage drug development companies and has particular interest in oncology and orphan or rare diseases. Within medical technology, the firm considers all device classes but generally favors companies approaching commercialization. In healthtech, the firm prioritizes solutions with demonstrated willingness to pay and sustainable business models, with a particular preference for B2B opportunities. 

From a company and management team perspective, the firm seeks private companies with strong development or commercial potential and takes an active approach following investment. The firm generally seeks board representation and works closely with portfolio companies as they progress through clinical development, commercialization, growth, and potential exit opportunities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.